Figure 1.
NRM in the clinical risk models. Six-month cumulative incidence of NRM by Minnesota (left) and Manhattan (right) risk strata. (A) Training cohort. Minnesota standard risk: 10.2% (95% CI, 8.5-12.2); Minnesota high risk: 36.8% (95% CI, 30.5-43.0); Manhattan low risk: 7.1% (95% CI, 5.1- 9.5); Manhattan intermediate risk: 13.9% (95% CI, 11.1-16.9); Manhattan high risk: 37.8% (95% CI, 31.2-44.4). (B) Validation cohort. Minnesota standard risk: 11.0% (95% CI, 8.3-14.1); Minnesota high risk: 34.4% (95% CI, 25.3-43.6); Manhattan low risk: 7.0% (95% CI, 4.2-10.8); Manhattan intermediate risk: 14.9% (95% CI, 10.6-19.9); Manhattan high risk: 35.8% (95% CI, 26.4-45.4). Pie charts depict the percentage of each clinical risk. ∗P values for pairwise comparisons were adjusted using the Bonferroni method.

NRM in the clinical risk models. Six-month cumulative incidence of NRM by Minnesota (left) and Manhattan (right) risk strata. (A) Training cohort. Minnesota standard risk: 10.2% (95% CI, 8.5-12.2); Minnesota high risk: 36.8% (95% CI, 30.5-43.0); Manhattan low risk: 7.1% (95% CI, 5.1- 9.5); Manhattan intermediate risk: 13.9% (95% CI, 11.1-16.9); Manhattan high risk: 37.8% (95% CI, 31.2-44.4). (B) Validation cohort. Minnesota standard risk: 11.0% (95% CI, 8.3-14.1); Minnesota high risk: 34.4% (95% CI, 25.3-43.6); Manhattan low risk: 7.0% (95% CI, 4.2-10.8); Manhattan intermediate risk: 14.9% (95% CI, 10.6-19.9); Manhattan high risk: 35.8% (95% CI, 26.4-45.4). Pie charts depict the percentage of each clinical risk. ∗P values for pairwise comparisons were adjusted using the Bonferroni method.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal